As per my $1/share post I pretty much agree with most of what has been said today as far as valuing Zenith goes. One small thing however, I disagree with Don getting too much credit for keeping the money coming in. I think most of the credit belongs to the science. I was in fact at the meeting after Eastern initially invested in RVX and Don was, rightfully so, talking about how great the science is and that he hadn't sought Eastern out but that Eastern had found RVX through the science. Maybe he sought out Hepalink, I don't know, but since the vast bulk of funding has come via Eastern let's give credit where it is due. Although I find Don to be likeable and he seems to work very hard I think his management team needs to be much more effective in general. To me if Don was as good as his billing he would have already effected the split of Zenith we voted on in January, he would have found Zenith Epigenetics another source of funding for this round and Zenith Capital Corporation would have not been diluted (as Don had said was his goal in January)